Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that despite its higher cost, Boehringer Ingelheim/Pfizer's Spiriva consistently leads both GlaxoSmithKline's Serevent and Astellas/Schering-Plough/Novartis's Foradil by a wide margin in first-, second-, and third-line therapy for moderate COPD. All three of these long- acting single agent bronchodilators are recommended for use as first-line maintenance treatment of moderate COPD.

According to the new report entitled Treatment Algorithms in COPD, although pulmonologists and COPD guidelines recommend Spiriva as first-line maintenance therapy for patients with moderate COPD, Advair consistently garners greater patient share than Spiriva in every line of therapy, and primary care physicians are of divided opinion when choosing between the two drugs.

"Interviewed thought leaders believe that many primary care physicians turn to Advair in early lines of therapy in COPD because of their familiarity with inhaled corticosteroids in treating asthma," said Madhuri Borde, Ph.D., analyst at Decision Resources. "However, Spiriva does have its advantages as many specialists and primary care physicians rank Spiriva's greater improvement of lung function as a primary reason for choosing it over Advair. We also found that more primary care physicians than pulmonologists indicated that Spiriva's ability to decrease exacerbations is a primary reason to choose the anticholinergic over Advair."

Treatment Algorithms for COPD allows pharmaceutical organizations to quantify lines of therapy through primary research and patient-level data. Users can accomplish the following:

   - Understand current treatment patterns and anticipate future market      dynamics.    - Drive product growth through accurate knowledge of a product's      positioning among the lines of therapy and of why physicians use it at      that point.    - Target specific competitors that are preceding or following a product      and benefit from actionable analysis of the path to treatment and      physicians' decision parameters.    - Develop more sophisticated market-forecasting patient-flow models based      on unique, accurate information regarding the percentage of patients      receiving a product at specific stages in a line of therapy.    About Treatment Algorithm Insight Series 

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics® to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides the following:

   - Summary of U.S. medical practice based on interviews with leading      experts in the field.    - Qualitative diagnosis/referral/treatment algorithm for the United      States.    - Drug usage by lines of therapy (1st, 2nd, 3rd line).    - Discussion of key freeform combinations by lines of therapy.    - Product share (class and specific compound level) within each line of      therapy (1st, 2nd, 3rd line).    - Progression of therapy from key 1st line products.    - Pathway to key therapies from previous therapies.    - Qualitative analysis of 2-year forecast incorporating upcoming      launches, changes in reimbursement, etc.    About Decision Resources 

Decision Resources, Inc., ( ) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, or

Healthcare Media Advisory; Looking Ahead At 2007 -- Webinar

View Now